Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
Open Access
- 29 January 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 113 (5) , 1062-1070
Abstract
Veltuzumab is a humanized anti-CD20 monoclonal antibody with complementarity-determining regions (CDRs) identical to rituximab, except for one residue at the 101st position (Kabat numbering) in CDR3 of the variable heavy chain (VH), having aspartic acid (Asp) instead of asparagine (Asn), with framework regions of epratuzumab, a humanized anti-CD22 antibody. When compared with rituximab, veltuzumab has significantly reduced off-rates in 3 human lymphoma cell lines tested, aswell as increased complement-dependent cytotoxicity in 1 of 3 cell lines, but no other in vitro differences. Mutation studies confirmed that the differentiation of the off-rate between veltuzumab and rituximab is related to the single amino acid change in CDR3-VH. Studies of intraperitoneal and subcutaneous doses in mouse models of human lymphoma and in normal cynomolgus monkeys disclosed that low doses of veltuzumab control tumor growth or deplete circulating or sessile B cells. Low- and high-dose veltuzumab were significantly more effective in vivo than rituximab in 3 lymphoma models. These findings are consistent with activity in patients with non-Hodgkin lymphoma given low intravenous or subcutaneous doses of veltuzumab. Thus, changing Asn101 to Asp101 in CDR3-VH of rituximab is responsible for veltuzumab's lower off-rate and apparent improved potency in preclinical models that could translate into advantages in patients.Keywords
This publication has 30 references indexed in Scilit:
- Newer monoclonal antibodies for hematological malignanciesExperimental Hematology, 2008
- First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialBlood, 2008
- Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptideMolecular Immunology, 2008
- Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 studyBlood, 2008
- Mechanisms of killing by anti-CD20 monoclonal antibodiesMolecular Immunology, 2007
- Evaluation of the Binding of Radiolabeled Rituximab to CD20-Positive Lymphoma Cells: An In Vitro Feasibility Study Concerning Low-Dose-Rate Radioimmunotherapy with the α -Emitter 227 ThCancer Biotherapy and Radiopharmaceuticals, 2007
- Follicular NHL: From Antibodies and Vaccines to Graft-versus-Lymphoma EffectsHematology-American Society Hematology Education Program, 2007
- Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursorBlood, 2006
- Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasBlood, 2004
- Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s LymphomaClinical Cancer Research, 2004